Tracers / [18F]BTK-1
[18F]BTK-1
Also written as [18F]BTK-1; [F-18]BTK-1
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- —
- Target / mechanism
- Bruton's tyrosine kinase (BTK) PMID 35482146
- Clinical application
- B cell malignancies and autoimmune disorders PMID 35482146
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | 6% yes | 99% | — | 35482146 2022 Mol Imaging Biol on a GE FX-FN TracerLab synthesis module — 6% decay-corrected radiochemical yield |
Need this precursor?We can point you to suppliers for [18F]BTK-1, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]BTK-1.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with F-18.